When the FRAX® test is applied to controlled clinical trials

Clinical Cases in Mineral and Bone Metabolism

Volumn 9, Issue 3, 2012, Pages 135-137

  Fiore, Carmelo Erio ^a   Gaudio, Agostino ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Alendronate; Bazedoxifene; Clodronate; Denosumab; FRAX ; Raloxifene; Strontium ranelate

Indexed keywords

ALCOHOL; ALENDRONIC ACID; BAZEDOXIFENE; CLODRONIC ACID; DENOSUMAB; GLUCOCORTICOID; PLACEBO; RALOXIFENE; STRONTIUM RANELATE;

ALCOHOL CONSUMPTION; ALGORITHM; BODY MASS; BONE DENSITY; CALCULATION; COMPUTER; DRUG EFFICACY; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; LONG TERM CARE; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK FACTOR; SHORT SURVEY; SMOKING; SPINE FRACTURE; WRIST FRACTURE;

EID: 84871859820     PISSN: 17248914     EISSN: 19713266     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (18)

1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Geneva, World Health Organization, 1994 (WHO Technical Report Series, No. 843).
2. WHO scientific group on the assessment of osteoporosis at primary health care level. Summary Meeting Report. Brussels, Belgium 5-7 May 2004, World Health Organization, 2007.
3. McCloskey EV, Johansson H, Oden A, et al. From relative risk to absolute fracture risk calculation: the FRAX algorithm. Curr Osteoporos Rep 2009;7(3):77-83.
4. Kanis JA, Hans D, Cooper C, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int 2011;22:2395-2411.
5. Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP/EWP/552/95Rev.2. London: CHMP; 2006.
6. McCloskey EV, Johansson H, Oden A, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapyadditional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 2009;20:811-817.
7. Cummings SR, Donaldson ML, Palermo L, et al. Efficacy of alendronate for reducing nonvertebral and clinical fractures by FRAX score. J Bone Miner Res 2009;24(suppl 1):S10.
8. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-645. (Pubitemid 29384151)
9. Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and non vertebral fractures: results from the MORE trial. Bone 2003;33:522-532. (Pubitemid 37222378)
10. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX® . Bone 2010;47:729-735.
11. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo, and activecontrolled clinical trial. J Bone Miner Res 2008;23(12):1923-1934.
12. Kanis JA, Johansson H, Oden A, et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009;44(6):1049-1054.
13. Chattopadhyay N, Quinn SJ, Kifor O, et al. The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol 2007;74:438-447. (Pubitemid 46970843)
14. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-468. (Pubitemid 38133766)
15. Reginster J-Y, Seeman E, De Vernejoul MC, et al. Strontium ranelate ranelate reduces the risk of nonvertebral fracture in postmenopausal women with osteoporosis: TROPOS study. J Clinl Endocrinol Metab 2005;90:2816-2822. (Pubitemid 40686329)
16. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX® . Osteoporos Int 2011;22(8):2347-2355.
17. Cummings SR, San Martin J, McClung MR, et al. Denosumab for preventionof fractures in postmenopausal women with osteoporosis. N Engl JMed 2009;361(8):756-765.
18. McCloskey EV, Johansson H, Oden A, et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women,particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 2012;27(7):1480-1486.